RBMS2 is an RNA-binding protein that functions as a tumor suppressor across multiple cancer types through post-transcriptional gene regulation. Mechanistically, RBMS2 directly binds AU-rich elements in the 3'-UTR of target mRNAs to stabilize their expression 1. In breast cancer, RBMS2 stabilizes P21 (CDKN1A) mRNA, promoting cell cycle arrest and inhibiting proliferation 12. RBMS2 also enhances doxorubicin chemosensitivity by upregulating BMF, which triggers apoptosis through caspase activation 2. In colorectal cancer, RBMS2 destabilizes SLC7A11 mRNA, promoting ferroptosis and suppressing tumor growth and metastasis 3. Additionally, RBMS2 is downregulated in 5-FU-resistant colorectal cancer cells, linking its loss to chemoresistance 4. In renal clear cell carcinoma, elevated RBMS2 expression correlates with reduced TNM staging and improved prognosis, with RBMS2 overexpression inhibiting cell proliferation and migration 5. Conversely, in gastric cancer, the lncRNA LINC01094 recruits RBMS2 and HDAC1 to suppress CDKN1A expression, promoting tumorigenesis 6. RBMS2 has been identified as a susceptibility gene for obstructive sleep apnea through inflammatory protein associations 7.